4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Sagimet Biosciences Inc. (SGMT) operates in the Biotechnology industry and is headquartered in San Mateo, United States with about 16 employees. Its market capitalization is roughly $442 million. In the fiscal year ended 2025-12-31, SGMT reported $0M in revenue and ($51M) in net income.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $2M | $0M | — |
| Operating Income (EBIT) | ($57M) | ($54M) | ($31M) | ($31M) | — |
| Net Income | ($51M) | ($46M) | ($28M) | ($30M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($12M) | ($11M) | ($14M) | ($12M) | ($20M) |
| Net Income | ($11M) | ($10M) | ($13M) | ($10M) | ($18M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $116M | $160M | $97M | $33M | — |
| Total Liabilities | $5M | $4M | $6M | $220M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SGMT viewer.
About TickerBase · Data methodology & sources